000283200 001__ 283200
000283200 005__ 20240229155050.0
000283200 0247_ $$2doi$$a10.3390/cells12182237
000283200 0247_ $$2pmid$$apmid:37759462
000283200 0247_ $$2altmetric$$aaltmetric:154069586
000283200 037__ $$aDKFZ-2023-01965
000283200 041__ $$aEnglish
000283200 082__ $$a570
000283200 1001_ $$aHamid, Rasha$$b0
000283200 245__ $$aThe Role and Therapeutic Targeting of CCR5 in Breast Cancer.
000283200 260__ $$aBasel$$bMDPI$$c2023
000283200 3367_ $$2DRIVER$$aarticle
000283200 3367_ $$2DataCite$$aOutput Types/Journal article
000283200 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1695986855_24400$$xReview Article
000283200 3367_ $$2BibTeX$$aARTICLE
000283200 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000283200 3367_ $$00$$2EndNote$$aJournal Article
000283200 520__ $$aThe G-protein-coupled receptor C-C chemokine receptor 5 (CCR5) functions as a co-receptor for the entry of HIV into immune cells. CCR5 binds promiscuously to a diverse array of ligands initiating cell signaling that includes guided migration. Although well known to be expressed on immune cells, recent studies have shown the induction of CCR5 on the surface of breast cancer epithelial cells. The function of CCR5 on breast cancer epithelial cells includes the induction of aberrant cell survival signaling and tropism towards chemo attractants. As CCR5 is not expressed on normal epithelium, the receptor provides a potential useful target for therapy. Inhibitors of CCR5 (CCR5i), either small molecules (maraviroc, vicriviroc) or humanized monoclonal antibodies (leronlimab) have shown anti-tumor and anti-metastatic properties in preclinical studies. In early clinical studies, reviewed herein, CCR5i have shown promising results and evidence for effects on both the tumor and the anti-tumor immune response. Current clinical studies have therefore included combination therapy approaches with checkpoint inhibitors.
000283200 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000283200 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000283200 650_7 $$2Other$$aCCR5
000283200 650_7 $$2Other$$abreast cancer
000283200 650_7 $$2Other$$atriple-negative breast cancer
000283200 7001_ $$aAlaziz, Mustafa$$b1
000283200 7001_ $$aMahal, Amanpreet S$$b2
000283200 7001_ $$00000-0001-6063-1566$$aAshton, Anthony W$$b3
000283200 7001_ $$0P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aHalama, Niels$$b4$$udkfz
000283200 7001_ $$0P:(DE-HGF)0$$aJaeger, Dirk$$b5
000283200 7001_ $$aJiao, Xuanmao$$b6
000283200 7001_ $$00000-0003-3244-8777$$aPestell, Richard G$$b7
000283200 773__ $$0PERI:(DE-600)2661518-6$$a10.3390/cells12182237$$gVol. 12, no. 18, p. 2237 -$$n18$$p2237$$tCells$$v12$$x2073-4409$$y2023
000283200 909CO $$ooai:inrepo02.dkfz.de:283200$$pVDB
000283200 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000283200 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000283200 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000283200 9141_ $$y2023
000283200 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-01-07T08:42:17Z
000283200 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-30
000283200 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-30
000283200 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-30
000283200 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-30
000283200 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-30
000283200 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCELLS-BASEL : 2022$$d2023-10-26
000283200 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000283200 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000283200 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000283200 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-08-01T15:15:06Z
000283200 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-08-01T15:15:06Z
000283200 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-08-01T15:15:06Z
000283200 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000283200 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000283200 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000283200 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000283200 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000283200 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCELLS-BASEL : 2022$$d2023-10-26
000283200 9201_ $$0I:(DE-He78)D240-20160331$$kD240$$lTranslationale Immuntherapie$$x0
000283200 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lD120 Angewandte Tumor-Immunität$$x1
000283200 980__ $$ajournal
000283200 980__ $$aVDB
000283200 980__ $$aI:(DE-He78)D240-20160331
000283200 980__ $$aI:(DE-He78)D120-20160331
000283200 980__ $$aUNRESTRICTED